Health Care-Related Economic Burden of the Polycystic Ovary Syndrome during the Reproductive Life Span
The DOI matches its Crossref record; 89 of the 90 references it cites were found in a registry or an index.
Abstract
CONTEXT: The polycystic ovary syndrome (PCOS) is the most common endocrine abnormality of reproductive-aged women today, affecting approximately 6.6% of unselected reproductive-aged women (approximately 4 million women in the United States) (1990 National Institutes of Health criteria), and potentially represents a significant financial burden to our health care. OBJECTIVE: The objective of the study was to define, using current definitions and prevalence or incidence data, the minimal economic burden that PCOS in reproductive-aged women represents for the United States. DESIGN: The study design was a literature review. SETTING: The study was conducted at a tertiary care center. PATIENTS OR OTHER PARTICIPANTS: There were no patients or other participants. INTERVENTION(S): We performed a systematic review of the published medical literature to identify studies evaluating epidemiology of reproductive-age PCOS and its clinical consequences and costs. We tied general societal cost data for the different health consequences to reproductive-age PCOS costs, using prevalence data. MAIN OUTCOME MEASURE(S): The main measure in the study was total health care-related economic costs. RESULTS: We estimated the mean annual cost of the initial evaluation to be dollar 93 million (2.1% of total costs), that of hormonally treating menstrual dysfunction/abnormal uterine bleeding to be dollar 1.35 billion (31.0% of total), that of providing infertility care to be dollar 533 million (12.2% of total), that of PCOS-associated diabetes to be dollar 1.77 billion (40.5% of total), and that of treating hirsutism to be dollar 622 million (14.2% of total). CONCLUSIONS: The total cost of evaluating and providing care to reproductive-aged PCOS women in the United States is dollar 4.36 billion. Because the cost of the diagnostic evaluation accounted for a relatively minor part of the total costs (approximately 2%), more widespread and liberal screening for the disorder appears be a cost-effective strategy, leading to earlier diagnosis and intervention and possibly the amelioration and prevention of serious sequelae.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“comprehensive screening and counseling from physicians and greater public awareness can curtail morbidity and reduce the economic burden on both the patient and the healthcare system.”
From 'I'm usually being my own doctor': women's experiences of managing polycystic ovary syndrome in Canada (2023) · cites this paper as [61]
In the citing paper
“PCOS has a high healthcare-related economic burden”
From 'I'm usually being my own doctor': women's experiences of managing polycystic ovary syndrome in Canada (2023) · cites this paper as [61]
In the citing paper
“Also from a resource allocation perspective, the financial costs related to diagnosis of PCOS are only a small fraction (2%) of the total costs associated with comprehensive care for PCOS in the United States (32).”
From Delayed Diagnosis and a Lack of Information Associated With Dissatisfaction in Women With Polycystic Ovary Syndrome (2016) · cites this paper as [32]
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,712
Self-citationMen at risk: occupation and male infertility
Claman, P. (2004) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01188-9 · Cited by 2,387
Amenorrhea associated with bilateral polycystic ovaries
Stein, I. F., & Leventhal, M. L. (1935) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(15)30642-6 · Cited by 2,121
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Knochenhauer, E. S., Key, T. J., Kahsar-Miller, M., Waggoner, W., Boots, L. R., & Azziz, R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.9.5090 · Cited by 1,516
Self-citationAsunción, M., Calvo, R. M., San Millán, J. L., Sancho, J., Avila, S., & Escobar-Morreale, H. F. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6682 · Cited by 1,318
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257
Androgen Excess in Women: Experience with Over 1000 Consecutive Patients
Azziz, R., Sanchez, L. A., Knochenhauer, E. S., Moran, C., Lazenby, J., Stephens, K. C., Taylor, K., & Boots, L. R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031122 · Cited by 1,132
Self-citation
Cited by
Endocrine-Disrupting Chemicals: An Endocrine Society Scientific Statement
Diamanti-Kandarakis, E., Bourguignon, J.-P., Giudice, L. C., Hauser, R., Prins, G. S., Soto, A. M., Zoeller, R. T., & Gore, A. C. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0002 · Cited by 4,585
“4 billion in the United States alone (68).”
BackgroundAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143
“dometrial carcinoma, obesity, type 2 diabetes mellitus, dyslipidemia, hypertension, and possibly cardiovascular disease (5).”
BackgroundSelf-citationAzziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.57 · Cited by 2,005
Self-citationTeede, H., Deeks, A., & Moran, L. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-41 · Cited by 1,565
“PCOS has also been noted to affect 28% of unselected obese and 5% of lean women [5-8].”
Norman, R. J., Dewailly, D., Legro, R. S., & Hickey, T. E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61345-2 · Cited by 1,360
Moran, L. J., Misso, M. L., Wild, R. A., & Norman, R. J. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmq001 · Cited by 1,108
The physiology and clinical utility of anti-Müllerian hormone in women
Dewailly, D., Andersen, C. Y., Balen, A., Broekmans, F., Dilaver, N., Fanchin, R., Griesinger, G., Kelsey, T. W., La Marca, A., Lambalk, C., et al. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmt062 · Cited by 1,049
Lim, S. S., Davies, M. J., Norman, R. J., & Moran, L. J. (2012) · Human Reproduction Update · doi:10.1093/humupd/dms030 · Cited by 939
“It was estimated that over $4 billion per year in the USA were spent on PCOS and its co-morbidities, identifying PCOS as a significant economic burden to health care (Azziz et al., 2005).”
BackgroundJoham, A. E., Norman, R. J., Stener-Victorin, E., Legro, R. S., Franks, S., Moran, L. J., Boyle, J., & Teede, H. J. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00163-2 · Cited by 838
Franks, S. (1997) · Archives of Disease in Childhood · doi:10.1136/adc.77.1.89 · Cited by 806
Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub5 · Cited by 698
The polycystic ovary syndrome: a position statement from the European Society of Endocrinology
Conway, G., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Franks, S., Gambineri, A., Kelestimur, F., Macut, D., Micic, D., Pasquali, R., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0253 · Cited by 676
“10 6 sites dedicated to the syndrome) and, in addition, identification and management of PCOS have been estimated to cost the USA healthcare system $4 billion annually (2).”
Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics
Singh, S., Pal, N., Shubham, S., Sarma, D. K., Verma, V., Marotta, F., & Kumar, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041454 · Cited by 521
“This high frequency, as well as its link with ovulation and menstruation abnormalities, infertility, hair loss, and metabolic issues, underscores PCOS’s significant financial burden [2,6].”
BackgroundStener-Victorin, E., Teede, H., Norman, R. J., Legro, R., Goodarzi, M. O., Dokras, A., Laven, J., Hoeger, K., & Piltonen, T. T. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00511-3 · Cited by 495
Diagnosis of Polycystic Ovarian Syndrome: The Rotterdam Criteria Are Premature
Azziz, R. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2153 · Cited by 432
Self-citationMoran, L. J., Pasquali, R., Teede, H. J., Hoeger, K. M., & Norman, R. J. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.09.018 · Cited by 444
Geographical Prevalence of Polycystic Ovary Syndrome as Determined by Region and Race/Ethnicity
Wolf, W. M., Wattick, R. A., Kinkade, O. N., & Olfert, M. D. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15112589 · Cited by 413
“It is suspected that there would be an increased prevalence of PCOS in Sri Lankan women when compared with Caucasians, due to the known link between type 2 Diabetes Mellitus and the high prevalence of diabetes in Sri Lanka [35,38].”
BackgroundGibson-Helm, M., Teede, H., Dunaif, A., & Dokras, A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2963 · Cited by 428
“The questionnaire was disseminated via the websites of the two largest PCOS support organizations worldwide: PCOS Challenge (USA) and Verity (UK).”
BackgroundInfluentialCassar, S., Misso, M. L., Hopkins, W. G., Shaw, C. S., Teede, H. J., & Stepto, N. K. (2016) · Human Reproduction · doi:10.1093/humrep/dew243 · Cited by 415
Impact of Obesity on the Risk for Polycystic Ovary Syndrome
Yildiz, B. O., Knochenhauer, E. S., & Azziz, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1834 · Cited by 401
Self-citationAnimal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome
Stener-Victorin, E., Padmanabhan, V., Walters, K. A., Campbell, R. E., Benrick, A., Giacobini, P., Dumesic, D. A., & Abbott, D. H. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa010 · Cited by 348
“Moreover, prevalence rates increase to over 25% in severely obese women with PCOS (15), and significant morbidity accompanies known associations with type 2 diabetes (T2D), cardiovascular dysfunction, obesity, infertility and cancer (2, 14, 16); hence, PCOS places a heavy burden on healthcare resources (17).”
BackgroundThe Potential Implications of a PCOS Diagnosis on a Woman's Long-Term Health Using Data Linkage
Hart, R., & Doherty, D. A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3886 · Cited by 391
Kakoly, N. S., Khomami, M. B., Joham, A. E., Cooray, S. D., Misso, M. L., Norman, R. J., Harrison, C. L., Ranasinha, S., Teede, H. J., & Moran, L. J. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmy007 · Cited by 384
Metabolic features of the reproductive phenotypes of polycystic ovary syndrome
Moran, L., & Teede, H. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp008 · Cited by 362
Poly Cystic Ovarian Syndrome: An Updated Overview
El Hayek, S., Bitar, L., Hamdar, L. H., Mirza, F. G., & Daoud, G. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00124 · Cited by 323
“Around 4 billion dollars are spent annually in the United States to screen for the disease and treat its various morbidities, including hirsutism, infertility, and diabetes mellitus (Azziz et al., 2005).”
BackgroundLim, S. S., Kakoly, N. S., Tan, J. W. J., Fitzgerald, G., Bahri Khomami, M., Joham, A. E., Cooray, S. D., Misso, M. L., Norman, R. J., Harrison, C. L., et al. (2019) · Obesity Reviews · doi:10.1111/obr.12762 · Cited by 316
“These metabolic co-morbidities are of significant economic impact, with PCOS-related diabetes accounting for 40% of the healthcare cost for PCOS (8).”
BackgroundTehrani, F., Simbar, M., Tohidi, M., Hosseinpanah, F., & Azizi, F. (2011) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-9-39 · Cited by 290
Morley, L. C., Tang, T., Yasmin, E., Norman, R. J., & Balen, A. H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub6 · Cited by 296
Polycystic ovary syndrome and its developmental origins
Dumesic, D. A., Abbott, D. H., & Padmanabhan, V. (2007) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-007-9046-0 · Cited by 283
“These estimates do not consider the greater frequency of pregnancy-related complications, including gestational diabetes, preeclampsia and miscarriage [1].”
BackgroundMethodInfluentialJoham, A. E., Teede, H. J., Ranasinha, S., Zoungas, S., & Boyle, J. (2015) · Journal of Women's Health · doi:10.1089/jwh.2014.5000 · Cited by 258
“33 The rate of use of fertility treatments is high in Australia, with the number of ART cycles initiated in Australia and New Zealand in 2009 increasing by 48% from 2005; 34 however, the proportion of these that have PCOS is unknown.”
Exercise therapy in polycystic ovary syndrome: a systematic review
Harrison, C. L., Lombard, C. B., Moran, L. J., & Teede, H. J. (2011) · Human Reproduction Update · doi:10.1093/humupd/dmq045 · Cited by 267
“36 billion was spend in 2004 on PCOS and its related complications with over 40% of this cost attributed to treating reproductive dysfunction (infertility, menstrual dysfunction) and a further 40% attributed to PCOS-related diabetes (Azziz et al., 2005).”
BackgroundInfluentialJoshi, B., Mukherjee, S., Patil, A., Purandare, A., Chauhan, S., & Vaidya, R. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.131162 · Cited by 228
“Polycystic ovarian syndrome (PCOS) is one of the most common reproductive endocrinological disorders with a broad spectrum of clinical manifestations affecting about 6-8% of women of reproductive years.[1] The diverse manifestations of PCOS start at an early age when a girl is maturing into a young woman.”
BackgroundDokras, A., Clifton, S., Futterweit, W., & Wild, R. (2011) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e318202b0a4 · Cited by 227
INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES
Baru, P. C. R. (2014) · ADVANCED SCIENCES INDEX · Cited by 236
Epigenetic inheritance of polycystic ovary syndrome — challenges and opportunities for treatment
Stener-Victorin, E., & Deng, Q. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00517-x · Cited by 212
Moore, A. M., Prescott, M., Marshall, C. J., Yip, S. H., & Campbell, R. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415038112 · Cited by 217
“Polycystic ovarian syndrome (PCOS), the most common form of anovulatory infertility (2), is estimated to affect more than 100 million women worldwide (3).”
BackgroundRisk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria
Shroff, R., Syrop, C. H., Davis, W., Van Voorhis, B. J., & Dokras, A. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.01.032 · Cited by 214
“Polycystic ovary syndrome is a significant economic burden to the modern health care system, underscoring the importance of accurate identification of women with the diagnosis (29).”
Vigorito, C., Giallauria, F., Palomba, S., Cascella, T., Manguso, F., Lucci, R., De Lorenzo, A., Tafuri, D., Lombardi, G., Colao, A., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2794 · Cited by 211
Riestenberg, C., Jagasia, A., Markovic, D., Buyalos, R. P., & Azziz, R. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab613 · Cited by 210
Self-citationCharacteristics of polycystic ovary syndrome throughout life
Louwers, Y. V., & Laven, J. S. E. (2020) · Therapeutic Advances in Reproductive Health · doi:10.1177/2633494120911038 · Cited by 174
Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: a review
Ashraf, S., Nabi, M., Rasool, S. U. A., Rashid, F., & Amin, S. (2019) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-019-0031-4 · Cited by 178
Oligoanovulation with Polycystic Ovaries But Not Overt Hyperandrogenism
Dewailly, D., Catteau-Jonard, S., Reyss, A.-C., Leroy, M., & Pigny, P. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1054 · Cited by 198
“There is therefore some fear that the Rotterdam classification leads to an overspill of the PCOS population, and this raises medical, psychological, and economic concerns (28).”
BackgroundReferral Bias in Defining the Phenotype and Prevalence of Obesity in Polycystic Ovary Syndrome
Ezeh, U., Yildiz, B. O., & Azziz, R. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1295 · Cited by 193
Self-citationDumont, A., Robin, G., Catteau-Jonard, S., & Dewailly, D. (2015) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-015-0134-9 · Cited by 183
“PCOS thus imposes a considerable economic burden on national health systems [46].”
BackgroundVagi, S. J., Azziz-Baumgartner, E., Sjödin, A., Calafat, A. M., Dumesic, D., Gonzalez, L., Kato, K., Silva, M. J., Ye, X., & Azziz, R. (2014) · BMC Endocrine Disorders · doi:10.1186/1472-6823-14-86 · Cited by 168
“3 billion [7].”
Self-citationDokras, A., Sarwer, D. B., Allison, K. C., Milman, L., Kris-Etherton, P. M., Kunselman, A. R., Stetter, C. M., Williams, N. I., Gnatuk, C. L., Estes, S. J., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1896 · Cited by 161
Rachoń, D., & Teede, H. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.09.026 · Cited by 161
“Increased serum insulin stimulates ovarian androgen production, but also reduces sex hormone binding globulin (SHBG) production in the liver further increasing serum levels of free bio-available androgens (Azziz et al., 2005).”
BackgroundMoore, A. M., Prescott, M., & Campbell, R. E. (2012) · Endocrinology · doi:10.1210/en.2012-1954 · Cited by 169
“802 Moore et al Estradiol Feedback in a Mouse Model of PCOS Endocrinology, February 2013, 154(2):796–806”
BackgroundMethodInfluentialIron Intake and Risk of Ovulatory Infertility
Chavarro, J. E., Rich-Edwards, J. W., Rosner, B. A., & Willett, W. C. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000238333.37423.ab · Cited by 153
Is foetal hyperexposure to androgens a cause of PCOS?
Filippou, P., & Homburg, R. (2017) · Human Reproduction Update · doi:10.1093/humupd/dmx013 · Cited by 152
Use of metformin in polycystic ovary syndrome
Mathur, R., Alexander, C. J., Yano, J., Trivax, B., & Azziz, R. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.09.010 · Cited by 180
Self-citationOrio, F., Palomba, S., Cascella, T., Simone, B. D., Manguso, F., Savastano, S., Russo, T., Tolino, A., Zullo, F., Lombardi, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0965 · Cited by 162
Self-citationBanaszewska, B., Pawelczyk, L., Spaczynski, R. Z., Dziura, J., & Duleba, A. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1988 · Cited by 143
Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome
Sharpe, A., Morley, L. C., Tang, T., Norman, R. J., & Balen, A. H. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013505 · Cited by 132
Therapeutic implications of vitamin D and calcium in overweight women with polycystic ovary syndrome
Pal, L., Berry, A., Coraluzzi, L., Kustan, E., Danton, C., Shaw, J., & Taylor, H. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2012.696753 · Cited by 137
“Given that millions are affected by PCOS worldwide [26], our observations, if substantiated by randomized controlled studies, suggest far reaching public health implications.”
BackgroundWitchel, S. F., Teede, H. J., & Peña, A. S. (2019) · Pediatric Research · doi:10.1038/s41390-019-0615-1 · Cited by 156
“Greater understanding of the genetics, epigenetics, hormonal dysregulations, and environmental factors is essential to inform new therapies and curtail the emotional distress, chronic health issues, and economic burden of this common disorder.(113) Available data suggest that multicomponent healthy lifestyle intervent…”
BackgroundMood and anxiety disorders in women with PCOS
Dokras, A. (2011) · Steroids · doi:10.1016/j.steroids.2011.12.008 · Cited by 152
The adrenal and polycystic ovary syndrome
Yıldız, B. O., & Azziz, R. (2007) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-007-9054-0 · Cited by 149
Self-citationEffects of lifestyle modification in polycystic ovarian syndrome
Moran, L., Brinkworth, G. D., Noakes, M., & Norman, R. J. (2006) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)61182-0 · Cited by 151
“5% of type 2 diabetesrelated costs (Azziz et al., 2005).”
The management of insulin resistance in polycystic ovary syndrome
Teede, H. J., Hutchison, S. K., & Zoungas, S. (2007) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2007.08.001 · Cited by 135
Polycystic Ovary Syndrome: Effect and Mechanisms of Acupuncture for Ovulation Induction
Johansson, J., & Stener‐Victorin, E. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/762615 · Cited by 150
Hyperandrogenic origins of polycystic ovary syndrome-Implications for Pathophysiology and Therapy
Abbott, D. H., Dumesic, D. A., & Levine, J. E. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1576522 · Cited by 131
“Despite the exceptionally high prevalence, its heavy burden on health-care resources, and substantial clinical and basic science research [2], PCOS remains”
BackgroundGeorge, J. T., Kakkar, R., Marshall, J., Scott, M. L., Finkelman, R. D., Ho, T. W., Veldhuis, J., Skorupskaite, K., Anderson, R. A., McIntosh, S., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1202 · Cited by 131
“In the long term, women with PCOS also have an increased risk of type 2 diabetes mellitus and potentially cardiovascular disease (6, 7).”
BackgroundInfluentialOrio, F., Muscogiuri, G., Nese, C., Palomba, S., Savastano, S., Tafuri, D., Colarieti, G., La Sala, G., Colao, A., & Yildiz, B. O. (2016) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2016.08.026 · Cited by 126
Insulin resistance and polycystic ovary syndrome
Galluzzo, A., Amato, M. C., & Giordano, C. S. D. S. (2008) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.05.004 · Cited by 137
Diagnosis of Polycystic Ovary Syndrome
TRIVAX, B., & AZZIZ, R. (2007) · Clinical Obstetrics and Gynecology · doi:10.1097/grf.0b013e31802f351b · Cited by 120
“Overall, the screening and evaluation of patients with possible PCOS is highly cost effective, representing only 2% of the economic burden of this disorder.(42)”
BackgroundSelf-citationSerum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome
Cascella, T., Palomba, S., Tauchmanovà, L., Manguso, F., Di Biase, S., Labella, D., Giallauria, F., Vigorito, C., Colao, A., Lombardi, G., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0399 · Cited by 120
Heutling, D., Schulz, H., Nickel, I., Kleinstein, J., Kaltwasser, P., Westphal, S., Mittermayer, F., Wolzt, M., Krzyzanowska, K., Randeva, H., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0842 · Cited by 117
“Polycystic ovary syndrome (PCOS) is the most frequent endocrine disorder of women in the reproductive age, affecting 5–10% of all women in this life span (1).”
BackgroundInfluentialSafiri, S., Noori, M., Nejadghaderi, S. A., Karamzad, N., Carson-Chahhoud, K., Sullman, M. J. M., Collins, G. S., Kolahi, A.-A., & Avery, J. (2022) · Human Reproduction · doi:10.1093/humrep/deac091 · Cited by 108
Zhao, Y., Tao, M., Wei, M., Du, S., Wang, H., & Wang, X. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1669619 · Cited by 122
“Other obstetrical complications are also reported to be linked with PCOS, such as type 2 diabetes mellitus (T2DM), hypertension and cardiovascular diseases [5].”
BackgroundPundir, J., Psaroudakis, D., Savnur, P., Bhide, P., Sabatini, L., Teede, H., Coomarasamy, A., & Thangaratinam, S. (2018) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.14754 · Cited by 115
Angiotensin-Converting Enzymes Play a Dominant Role in Fertility
Pan, P., Zhan, Q., Fang, L., Zheng, Y., & Jin, F. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141021071 · Cited by 119
“Polycystic ovary, which is the leading cause of anovulatory infertility, affects 5%–7% of women of reproductive age [9].”
BackgroundTay, C. T., Hart, R. J., Hickey, M., Moran, L. J., Earnest, A., Doherty, D. A., Teede, H. J., & Joham, A. E. (2020) · BMC Medicine · doi:10.1186/s12916-020-01861-x · Cited by 97
Ibáñez, L., & de Zegher, F. (2006) · Human Reproduction Update · doi:10.1093/humupd/dmi054 · Cited by 113
“…adolescents and young women; it is a condition that represents a major healthcare challenge, partly because of its co-morbidities including subfertility, dyslipidemia and cardiovascular disease (Asunción et al., 2000; Dunaif and Thomas, 2000; Azziz et al., 2004a, 2005; Buggs and Rosenfield, 2005).”
BackgroundArentz, S., Smith, C. A., Abbott, J. A., Fahey, P. P., Cheema, B. S., & Bensoussan, A. (2017) · Phytotherapy Research · doi:10.1002/ptr.5858 · Cited by 120
“, 2013a), and clinical uptake remains impeded by the lack of evidence for optimal dietary and exercise practices (Azziz et al., 2005).”
BackgroundInfluentialPolycystic Ovary Syndrome in the Pediatric Population
Bremer, A. A. (2010) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2010.0039 · Cited by 94
“In the United States alone, it is also associated with an economic burden exceeding four billion dollars.(9) PCOS is primarily characterized by: (1) Menstrual dysfunction (oligo- or amenorrhea), (2) cutaneous signs of hyperandrogenism (acne, hirsutism, or alopecia), (3) obesity, (4) disordered gonadotropin [luteinizin…”
Zhang, J., Fan, P., Liu, H., Bai, H., Wang, Y., & Zhang, F. (2012) · Human Reproduction · doi:10.1093/humrep/des191 · Cited by 108
“PCOS thus is a complex condition that impacts on health across the lifespan and represents a major health and economic burden (Azziz et al., 2005; Moran and Teede, 2009; Teede et al., 2010).”
BackgroundDiet and Nutrition in Gynecological Disorders: A Focus on Clinical Studies
Afrin, S., AlAshqar, A., Sabeh, M. E., Miyashita‐Ishiwata, M., Reschke, L. D., Brennan, J. T., Fader, A. N., & Borahay, M. A. (2021) · Nutrients · doi:10.3390/nu13061747 · Cited by 108
Islam, H., Masud, J., Islam, Y. N., & Haque, F. K. M. (2022) · Women s Health · doi:10.1177/17455057221117966 · Cited by 130
Dermatologic Manifestations of Polycystic Ovary Syndrome
Lee, A. T., & Zane, L. T. (2007) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200708040-00003 · Cited by 109
Polycystic Ovary Syndrome in Adolescence
Blank, S. K., Helm, K. D., McCartney, C. R., & Marshall, J. C. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1429.005 · Cited by 97
Burden of polycystic ovary syndrome in the Middle East and North Africa region, 1990–2019
Asghari, K. M., Nejadghaderi, S. A., Alizadeh, M., Sanaie, S., Sullman, M. J. M., Kolahi, A., Avery, J., & Safiri, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-11006-0 · Cited by 120
Popovic, M., Sartorius, G. A., & Christ‐Crain, M. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00737-4 · Cited by 103
Siristatidis, C. S., Vrachnis, N., Creatsa, M., Maheshwari, A., & Bhattacharya, S. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006606.pub3 · Cited by 93
Intrauterine Environment and Polycystic Ovary Syndrome
Goodarzi, M. O., Chazenbalk, G. D., Abbott, D. H., & Dumesic, D. A. (2014) · Seminars in Reproductive Medicine · doi:10.1055/s-0034-1371087 · Cited by 100
Linkage of regulators of TGF‐β activity in the fetal ovary to polycystic ovary syndrome
Hatzirodos, N., Bayne, R. A., Irving‐Rodgers, H. F., Hummitzsch, K., Sabatier, L., Lee, S., Bonner, W., Gibson, M. A., Rainey, W. E., Carr, B. R., et al. (2011) · The FASEB Journal · doi:10.1096/fj.11-181099 · Cited by 90
“Polycystic ovary syndrome (PCOS) is a major burden on health costs (1) and is the commonest endocrine condition affecting women of reproductive age in”
BackgroundBanaszewska, B., Pawelczyk, L. A., Spaczyński, R., & Dulęba, A. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1674 · Cited by 96
Deep Learning Algorithm for Automated Detection of Polycystic Ovary Syndrome Using Scleral Images
Lv, W., Song, Y., Fu, R., Lin, X., Su, Y., Jin, X., Yang, H., Shan, X., Du, W., Huang, Q., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.789878 · Cited by 101
“It is estimated that the average cost of initial diagnosis and evaluation of PCOS is $740 (4), which is a significant financial burden.”
BackgroundYadav, S., Delau, O., Bonner, A. J., Markovic, D., Patterson, W., Ottey, S., Buyalos, R. P., & Azziz, R. (2023) · eLife · doi:10.7554/elife.85338 · Cited by 85
Self-citationCardiopulmonary Impairment in Young Women with Polycystic Ovary Syndrome
Orio, F., Giallauria, F., Palomba, S., Cascella, T., Manguso, F., Vuolo, L., Russo, T., Tolino, A., Lombardi, G., Colao, A., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0216 · Cited by 84
Challenges and improvements in testosterone and estradiol testing
Vesper, H. W., Cook-Botelho, J. C., & Wang, Y. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122338 · Cited by 88
New biomarkers for diagnosis and management of polycystic ovary syndrome
Karakas, S. E. (2017) · Clinica Chimica Acta · doi:10.1016/j.cca.2017.06.009 · Cited by 89
Obsekov, V., Kahn, L. G., & Trasande, L. (2023) · Exposure and Health · doi:10.1007/s12403-022-00496-y · Cited by 71
“37 billion for 4 million women or $1092 per PCOS case in 2004 dollars (Azziz et al. 2005).”
BackgroundEpidemiology and Comorbidities of Polycystic Ovary Syndrome in an Indigent Population
Sirmans, S. M., Parish, R. C., Blake, S., & Wang, X. (2014) · Journal of Investigative Medicine · doi:10.1097/01.jim.0000446834.90599.5d · Cited by 79
“3% of the overall economic burden.(25) However, evidence suggests that, in contemporary clinical practice, PCOS is underrecognized.”
BackgroundDiagnosis and Management of Polycystic Ovary Syndrome in Adolescents
Trent, M., & Gordon, C. M. (2020) · PEDIATRICS · doi:10.1542/peds.2019-2056j · Cited by 84
“term cardiovascular, metabolic, and reproductive health outcomes(4); and annual clinical management costs that exceed $4 billion annually.(5) In this article, we will highlight current”
BackgroundYasmin, A., Roychoudhury, S., Choudhury, A. P., Ahmed, A. B. F., Dutta, S., Mottola, F., Verma, V., Kalita, J. C., Kumar, D., Sengupta, P., et al. (2022) · Life · doi:10.3390/life12121974 · Cited by 94
Hu, M., Zhang, Y., Ma, S., Li, J., Wang, X., Liang, M., Sferruzzi-Perri, A. N., Wu, X., Ma, H., Brännström, M., et al. (2021) · Molecular Human Reproduction · doi:10.1093/molehr/gaab067 · Cited by 79
Cardio-Metabolic Disease and Polycystic Ovarian Syndrome (PCOS): A Narrative Review
Sangaraju, S. L., Yepez, D., Grandes, X. A., Manjunatha, R. T., & Habib, S. (2022) · Cureus · doi:10.7759/cureus.25076 · Cited by 95
“According to USA data, the burden of PCOS in Australia can be accounted for AU$ four billion [60,61].”
MethodPerspectives on polycystic ovary syndrome: Is polycystic ovary syndrome research underfunded?
Brakta, S., Lizneva, D., Mykhalchenko, K., Imam, A., Walker, W., Diamond, M. P., & Azziz, R. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01415 · Cited by 76
Self-citationKatsigianni, M., Karageorgiou, V., Lambrinoudaki, I. V., & Siristatidis, C. S. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0398-0 · Cited by 76
“infertility services at some point in their life [2].”
Background
Metadata
- Authors
- Azziz, R., Marin, C., Hoq, L., Badamgarav, E., & Song, P.
- Affiliations
- Cedars-Sinai Medical Center (US)
- ORCID
- Azziz, Ricardo
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-08
- Volume
- 90
- Issue
- 8
- Pages
- 4650-4658
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2118575626
- Cited by
- 537
- References
- 90
- Citations by year
- 2026: 20 · 2025: 30 · 2024: 29 · 2023: 28 · 2022: 36 · 2021: 45 · 2020: 25 · 2019: 41 · 2018: 27 · 2017: 27 · 2016: 22 · 2015: 20 · 2014: 27 · 2013: 24 · 2012: 26
- FWCI
- 18.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (K24-D01346)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD029364, R01-HD29364)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- polycystic ovary syndrome, economic burden, health care costs, women of reproductive age, infertility treatment, hirsutism, abnormal uterine bleeding, menstrual disorders, PCOS screening, cost estimation
- MeSH terms
- Adolescent, Adult, Female, Humans, Polycystic Ovary Syndrome, United States, Incidence, Prevalence, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.